title: Antibodies Create Killer Bonds in Myeloma.
abstract: In this issue of Cancer Cell, Li et al. and Seckinger et al. describe promising results of two T-cell-dependent bi-specific antibodies for the treatment of multiple myeloma: one targets FcRH5 expressed on B cells, whereas the other targets the B cell maturation antigen expressed on plasma cells.
authors.affiliation: Mayo Clinic in Arizona, Phoenix, AZ 85054, USA.
authors.forename: Marta
authors.initials: M
authors.lastname: Chesi
authors.affiliation: Mayo Clinic in Arizona, Phoenix, AZ 85054, USA. Electronic address: fonseca.rafael@mayo.edu.
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
mesh_terms: D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D053301:B-Cell Maturation Antigen / Q000276:immunology*; D001402:B-Lymphocytes; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D010950:Plasma Cells
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D053301:B-Cell Maturation Antigen